U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
SEC File Number: 001-10382
CUSIP Number:
(Check One) Form 10-K [ ] Form 20-F [ ] Form 10-Q [X] Form N-SAR [ ]
For Period Ended: June 30, 2002
----------------
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended: ________________________
---------------------------------------------------------
Nothing in this form shall be construed to imply that the
Commission has verified any information contained herein.
---------------------------------------------------------
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:
- ------------------------------------------------------------------------------
PART I - REGISTRANT INFORMATION
- ------------------------------------------------------------------------------
Full Name of Registrant: GoHealth.MD, Inc.
Former Name if Applicable: Nugget Exploration, Inc.
Address of Principal Executive Office (Street and Number):
City, State, Zip Code:
c/o David Reichman
148 Madison Avenue, 14th Floor
New York, NY 10018
- ------------------------------------------------------------------------------
PART II - RULES 12b-25 (b) AND (c)
- ------------------------------------------------------------------------------
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate)
(a) The reasons described in reasonable detail in Part III of this
form could not be eliminated without unreasonable effort or
expense
[X] (b) The subject annual report, semi-annual report, transition report
on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof,
will be filed on or before the fifteenth calendar day following
the prescribed due date; or the subject quarterly report of
transition report on Form 10-Q, or portion thereof will be filed
on or before the fifth calendar day following the prescribed due
date; and
(c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
- ------------------------------------------------------------------------------
PART III - NARRATIVE
- ------------------------------------------------------------------------------
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q,
N-SAR or the transition report or portion thereof could not be filed within
the prescribed time period.
The Company lacked certain information required in report. Officers of
the Company responsible for preparing the report have been unable to complete
information required in report because of this. The Company is therefore
seeking an extension to allow it suitable time to finish.
- ------------------------------------------------------------------------------
PART IV - OTHER INFORMATION
- ------------------------------------------------------------------------------
(1) Name and telephone number of person to contract in regard to this
notification:
William Hanna, CEO, Chairman, President,
Principal Financial Officer, and Director) (800) 204-1902
------------------------------------- ------------------
(Name and Title) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act or 1940 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports) been
filed? If answer is no, identify report(s). [X] Yes [ ] No
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected
by the earning statements to be included in the subject report or
portion thereof? [ ] Yes [X] No
If so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
GoHealth.MD, Inc.
--------------------------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
By: /s/ William Hanna
Date: August 14, 2002 ---------------------------------
-------------------- Name: William Hanna
Title: President and CEO
INSTRUCTION: The form may be signed by an executive officer of the registrant
or by any other duly authorized representative. The name and title of the
person signing the form shall be typed or printed beneath the signature. If
the statement is signed on behalf of the registrant by an authorized
representative (other than an executive officer), evidence of the
representative's authority to sign on behalf of the registrant shall be filed
with the form.